<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03509545</url>
  </required_header>
  <id_info>
    <org_study_id>CLCD-075-17</org_study_id>
    <nct_id>NCT03509545</nct_id>
  </id_info>
  <brief_title>Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide</brief_title>
  <official_title>An Open Label,Crossover Study to Compare Once Daily Dose of 40 mg Torsemide Extended Release to Twice Daily of Furosemide on Natriuresis and Body Weight in Congestive Heart Failure (CHF) Patients Who Are on Stable Dose of Furosemide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sarfez Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sarfez Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effects of 40 mg once-daily Torsemide ER to 40 mg twice daily Furosemide on
      24-hour sodium excretion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the effects of 40 mg once-daily Torsemide ER to 40 mg twice-daily Furosemide on
      changes in body weight after two weeks of treatment. To compare the frequency and volume of
      urine passed in 24 hours. To compare the patients' quality of life and levels of natriuretic
      peptide between the two sets of patients.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 17, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in 24-hour sodium excretion compared to baseline</measure>
    <time_frame>24 hours</time_frame>
    <description>the difference in 24 hour sodium excretion between ER Torsemide and Furosemide</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in body weight</measure>
    <time_frame>2 weeks</time_frame>
    <description>Body weight changes will be compared between the two arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Body Weight Changes</condition>
  <arm_group>
    <arm_group_label>CHF Patients: ER Torsemide 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHF patients will be given 40 mg ER Torsemide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF Patients: Furosemide 40 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CHF patients are on 40 mg of Furosemide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF Patients: ER Torsemide 40 mg</intervention_name>
    <description>ER Torsemide 40mg given once daily to CHF patients</description>
    <arm_group_label>CHF Patients: ER Torsemide 40 mg</arm_group_label>
    <other_name>Demadex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF Patients: Furosemide 40 mg</intervention_name>
    <description>Stable CHF patients taking twice-daily 40 mg Furosemide</description>
    <arm_group_label>CHF Patients: Furosemide 40 mg</arm_group_label>
    <other_name>Lasix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of either gender over 18 years of age with clinical diagnosis of CHF and on a
             stable dose of 40 mg Furosemide.

        Exclusion Criteria:

          -  Requirement for any other diuretic, history of cardiac dysrhythmia, other concurrent
             cardiovascular illness.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anil K, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Syngene International</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jaya Patel, MS</last_name>
    <phone>+91 8028082838</phone>
    <email>jaya.patel@syngeneint.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Syngene International</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560099</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2018</study_first_submitted>
  <study_first_submitted_qc>April 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2018</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>natriuresis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Body Weight Changes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
    <mesh_term>Torsemide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

